News from Naurex Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

13 Mar, 2015, 13:54 ET Naurex to Present at 22nd Annual BioCentury Future Leaders in the Biotech Industry Conference

 Naurex Inc., a biopharmaceutical company leveraging its unique platform to develop novel drugs for diseases of the central nervous system...


27 Jan, 2015, 08:00 ET Naurex's First Orally Active Molecule, NRX-1074, Demonstrates Statistically Significant Improvement in Depression Scores within 24 Hours in Phase 2 Study for Major Depressive Disorder

Naurex Inc., a biopharmaceutical company leveraging its unique platform to develop novel drugs for diseases of the central nervous system (CNS),...


19 Dec, 2014, 11:07 ET Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference

Naurex Inc., a biopharmaceutical company leveraging its unique platform to develop novel drugs for diseases of the central nervous system, today...


10 Dec, 2014, 08:00 ET Naurex's GLYX-13 Demonstrates Robust, Sustained Antidepressant Effects and Excellent Tolerability in Phase 2b Study

 Naurex Inc. today announced that Phase 2b data presented at the Annual Meeting of the American College of Neuropsychopharmacology demonstrated...


03 Dec, 2014, 07:30 ET Naurex Raises $80 Million in Series C Financing to Advance Novel NMDA Receptor Modulators in Depression and Other CNS Disorders

 Naurex Inc., a biopharmaceutical company leveraging its unique platform to develop novel drugs for diseases of the central nervous system...


17 Nov, 2014, 09:00 ET Data Presented at Society for Neuroscience Demonstrates that Naurex's GLYX-13 Enhances Synaptic Plasticity through NMDA Receptor Modulation

 Naurex Inc. today announced that data presented at the Society for Neuroscience conference demonstrate that the company's lead therapeutic...


15 May, 2014, 07:30 ET Naurex to Present at UBS Global Healthcare Conference

 Naurex Inc. today announced that its president and chief executive officer, Norbert G. Riedel, PhD, will present at the UBS Global Healthcare...


06 May, 2014, 07:30 ET Naurex Reports Positive Top-Line Phase 2b Results for Novel Antidepressant GLYX-13 and Advances NRX-1074 into Phase 2 Depression Study

Naurex Inc., a privately held biopharmaceutical company leveraging its unique platform to develop novel drugs for diseases of the central nervous...


09 Jan, 2014, 17:09 ET Naurex to Present at the 32nd Annual J.P. Morgan Healthcare Conference

Naurex Inc. today announced that Norbert G. Riedel, Ph.D., long-term board member and newly-appointed president and chief executive officer of...


08 Jan, 2014, 08:00 ET Naurex Names Dr. Norbert G. Riedel President and Chief Executive Officer

 Naurex Inc. today announced that Norbert G. Riedel, Ph.D., has been named president and chief executive officer effective January 1,...


12 Dec, 2013, 08:00 ET Naurex Presents Data on Rapid-Acting Antidepressant GLYX-13 that Support Long-term Synaptic Plasticity as Its Mechanism of Action

 Naurex Inc. today announced the presentation of preclinical data at the 52nd Annual Meeting of the American College of Neuropsychopharmacology...


30 Jul, 2013, 07:30 ET Naurex Announces Issuance Of New Patent For Novel Antidepressant GLYX-13

 Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced...


04 Jun, 2013, 07:30 ET Naurex Announces Initiation Of Phase I Trial For Second-Generation Novel Antidepressant Agent NRX-1074

 Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced...


17 Dec, 2012, 07:30 ET Naurex Completes $38 Million Series B Financing

 Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced the...


06 Dec, 2012, 07:30 ET Phase II Data Presented at ACNP 2012 Shows Novel Antidepressant GLYX-13 Significantly Reduces Depression Scores Within Hours

 Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today reported...


07 Nov, 2011, 08:00 ET Naurex's Novel Antidepressant GLYX-13 Recognized as One of Windhover's 2011 Top 10 Neuroscience Projects to Watch

 Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today...


22 Jun, 2011, 07:30 ET Naurex Initiates Phase II Clinical Trial of Novel Antidepressant GLYX-13 in Treatment-Resistant Depression

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced that it...


11 May, 2011, 07:00 ET Naurex Completes $18 Million Series A Financing

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced the...


07 Dec, 2010, 07:30 ET New Preclinical Data Confirm Naurex's Novel Antidepressant GLYX-13 Appears Free of the Behavioral Impairment and Abuse Potential Seen With Ketamine

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, reported that data being...


17 Nov, 2010, 07:30 ET Preclinical Data at Neuroscience 2010 Show Naurex's Novel Antidepressant GLYX-13 Shares Key Efficacy Mechanisms with Ketamine

Naurex Inc., a company developing innovative treatments to address unmet needs in psychiatry and neurology, today reported that data presented at...


31 Aug, 2010, 07:30 ET Naurex's Novel Antidepressant GLYX-13 Recognized as One of Windhover's Top 10 Neuroscience Projects to Watch

Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders, today reported that its clinical...